Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Evasion of immune system is a hallmark of cancer, which enables cancer cells to escape the attack from immune cells. Cancer cells can express many immune inhibitory signalling proteins to cause immune cell dysfunction and apoptosis. One of these inhibitory molecules is programmed death-ligand-1 (PD-L1), which binds to programmed death-1 (PD-1) expressed on T-cells, B-cells, dendritic cells and natural killer T-cells to suppress anti-cancer immunity. Therefore, anti-PD-L1 and anti-PD-1 antibodies have been used for the treatment of cancer, showing promising outcomes. However, only a proportion of patients respond to the treatments. Further understanding of the regulation of PD-L1 expression could be helpful for the improvement of anti-PD-L1 and anti-PD-1 treatments. Studies have shown that PD-L1 expression is regulated by signalling pathways, transcriptional factors and epigenetic factors. In this review, we summarise the recent progress of the regulation of PD-L1 expression in cancer cells and propose a regulatory model for unified explanation. Both PI3K and MAPK pathways are involved in PD-L1 regulation but the downstream molecules that control PD-L1 and cell proliferation may differ. Transcriptional factors hypoxia-inducible factor-1α and signal transducer and activation of transcription-3 act on the promoter of PD-L1 to regulate its expression. In addition, microRNAs including miR-570, miR-513, miR-197, miR-34a and miR-200 negatively regulate PD-L1. Clinically, it could increase treatment efficacy of targeted therapy by choosing those molecules that control both PD-L1 expression and cell proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of PI3K/AKT/mTOR signaling pathway would occur in 20% of CRC patients, and the activation of this pathway may be related to the expression of PD-L1 [224,225].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [224]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The activation of PI3K/AKT/mTOR signaling pathway would occur in 20% of CRC patients, and the activation of this pathway may be related to the expression of PD-L1 [224,225].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [224]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 5×
“Chen N, Fang W, Zhan J et al. Up-regulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.”
BackgroundInfluentialThe phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
PI3K: Downstream AKTion Blocks Apoptosis
Franke, T. F., Kaplan, D. R., & Cantley, L. C. (1997) · Cell · doi:10.1016/s0092-8674(00)81883-8 · Cited by 1,668
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185 · cited 1×
“The MAPK signalling pathway plays a critical role in cell survival and proliferation [47-49].”
BackgroundLinsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
Self-citationEvans, D. C., Schott, R. K., Larson, D. W., Brown, C. M., & Ryan, M. J. (2014) · Nature Communications · doi:10.1038/ncomms4289 · Cited by 940
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 698
Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 669
Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & Tokura, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 667
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
Mu, C.-Y., Huang, J.-A., Chen, Y., Chen, C., & Zhang, X.-G. (2011) · Medical Oncology · doi:10.1007/s12032-010-9515-2 · Cited by 577
Self-citationWin-Stay-Lose-Learn Promotes Cooperation in the Spatial Prisoner's Dilemma Game
Liu, Y., Chen, X., Zhang, L., Wang, L., & Perc, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030689 · Cited by 527
Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2731 · Cited by 485
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Kochenderfer, J. N., & Rosenberg, S. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 451
Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2339 · Cited by 446
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410
Self-citationFang, W., Zhang, J., Hong, S., Zhan, J., Chen, N., Qin, T., Tang, Y., Zhang, Y., Kang, S., Zhou, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2608 · Cited by 398
Alterations of immune response of non-small cell lung cancer with Azacytidine
Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F., VanCriekinge, W., DeMeyer, T., Du, Z., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1542 · Cited by 386
Integrating canonical and metabolic signalling programmes in the regulation of T cell responses
Pollizzi, K. N., & Powell, J. D. (2014) · Nature Reviews Immunology · doi:10.1038/nri3701 · Cited by 379
Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.137 · Cited by 322
Wang, X., Li, J., Dong, K., Lin, F., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 313
Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
Rosenberg, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.116 · Cited by 312
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Shi, L., Chen, S., Yang, L., & Li, Y. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-74 · Cited by 307
Weber, J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.005 · Cited by 306
Alsuliman, A., Colak, D., Al-Harazi, O., Fitwi, H., Tulbah, A., Al-Tweigeri, T., Al-Alwan, M., & Ghebeh, H. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0421-2 · Cited by 285
Melanoma cells influence the differentiation pattern of human epidermal keratinocytes
Kodet, O., Lacina, L., Krejčí, E., Dvořánková, B., Grim, M., Štork, J., Kodetová, D., Vlček, Č., Šáchová, J., Kolář, M., et al. (2015) · Molecular Cancer · doi:10.1186/1476-4598-14-1 · Cited by 267
Song, M., Chen, D., Lu, B., Wang, C., Zhang, J., Huang, L., Wang, X., Timmons, C. L., Hu, J., Liu, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065821 · Cited by 266
Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.10 · Cited by 261
Resistance to BRAF Inhibition in Melanomas
Solit, D. B., & Rosen, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmcibr1013704 · Cited by 243
Chen, Y., Wang, Q., Shi, B., Xu, P., Hu, Z., Bai, L., & Zhang, X. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.004 · Cited by 243
Self-citationGowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J., Rizos, H., & Hersey, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123410 · Cited by 230
Abiko, K., Mandai, M., Hamanishi, J., Yoshioka, Y., Matsumura, N., Baba, T., Yamaguchi, K., Murakami, R., Yamamoto, A., Kharma, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2199 · Cited by 221
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
La‐Beck, N. M., Jean, G. W., Huynh, C., Alzghari, S. K., & Lowe, D. B. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1643 · Cited by 216
Mechanisms of Hypoxia-Mediated Immune Escape in Cancer
Barsoum, I. B., Koti, M., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2598 · Cited by 201
Jardim, M. J., Fry, R. C., Jaspers, I., Dailey, L., & Diaz-Sanchez, D. (2009) · Environmental Health Perspectives · doi:10.1289/ehp.0900756 · Cited by 179
Pawelec, G., Derhovanessian, E., & Larbi, A. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.06.012 · Cited by 173
Hsu, M.-C., Hsiao, J., Chang, K., Wu, Y.-H., Su, I., Jin, Y., & Chang, Y. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.130 · Cited by 163
Multiple signal pathways in obesity-associated cancer: Obesity, signal pathways and cancer
Chen, J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00917.x · Cited by 162
Self-citationBalan, M., y Teran, E. M., Waaga-Gasser, A. M., Gasser, M., Choueiri, T. K., Freeman, G. J., & Pal, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612689 · Cited by 161
MicroRNA signatures in liver diseases
Chen, X. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1665 · Cited by 158
Wang, W., Li, F., Mao, Y., Zhou, H., Sun, J., Li, R., Liu, C., Chen, W., Hua, D., & Zhang, X. (2013) · Human Genetics · doi:10.1007/s00439-013-1275-6 · Cited by 154
Self-citationMassi, D., Brusa, D., Merelli, B., Ciano, M., Audrito, V., Serra, S., Buonincontri, R., Baroni, G., Nassini, R., Minocci, D., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu452 · Cited by 151
Cell cycle progression in response to oxygen levels
Ortmann, B. M., Druker, J., & Rocha, S. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1645-9 · Cited by 148
Blackburn, S. D., Crawford, A., Shin, H., Polley, A. M., Freeman, G. J., & Wherry, E. J. (2009) · Journal of Virology · doi:10.1128/jvi.01579-09 · Cited by 146
Lin, C., Chen, X., Li, M., Liu, J., Qi, X., Yang, W., Zhang, H., Cai, Z., Dai, Y., & Ouyang, X. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.02.002 · Cited by 121
Signaling pathways in HPV‐associated cancers and therapeutic implications
Chen, J. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1823 · Cited by 118
Self-citationCAR T cells: driving the road from the laboratory to the clinic
Cheadle, E. J., Gornall, H., Baldan, V., Hanson, V., Hawkins, R. E., & Gilham, D. E. (2013) · Immunological Reviews · doi:10.1111/imr.12126 · Cited by 115
Massi, D., Brusa, D., Merelli, B., Falcone, C., Xue, G., Carobbio, A., Nassini, R., Baroni, G., Tamborini, E., Cattaneo, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv255 · Cited by 105
Site-specific methylation of Notch1 controls the amplitude and duration of the Notch1 response
Hein, K., Mittler, G., Cizelsky, W., Kühl, M., Ferrante, F., Liefke, R., Berger, I. M., Just, S., Sträng, E., Kestler, H. A., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005892 · Cited by 102
Ye, Y., Jin, L., Wilmott, J. S., Hu, W. L., Yosufi, B., Thorne, R. F., Liu, T., Rizos, H., Yan, X. G., Dong, L., et al. (2013) · Nature Communications · doi:10.1038/ncomms2489 · Cited by 83
Self-citationCryptosporidium parvumInduces B7‐H1 Expression in Cholangiocytes by Down‐Regulating MicroRNA‐513
Gong, A., Zhou, R., Hu, G., Liu, J., Sosnowska, D., Drescher, K. M., Dong, H., & Chen, X. (2009) · The Journal of Infectious Diseases · doi:10.1086/648589 · Cited by 82
Qin, X., Liu, C., Zhou, Y., & Wang, G. (2010) · PubMed · Cited by 79
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Queirolo, P., Picasso, V., & Spagnolo, F. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.010 · Cited by 79
Targeting hypoxia at the forefront of anticancer immune responses
Noman, M. Z., & Chouaib, S. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954463 · Cited by 70
Cheng, H.-L. M., Liu, P., Zhang, F., Xu, E., Symonds, L. K., Ohlson, C. E., Bronson, R. T., Maira, S.-M., di Tomaso, E., Li, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0544 · Cited by 66
Borre, P. V., Gunda, V., McFadden, D. G., Sadow, P. M., Varmeh, S., Bernasconi, M. J., & Parangi, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2130 · Cited by 43
Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK Pathway
Gong, W., Song, Q., Lu, X., Gong, W., Zhao, J., Peng, M., & Yi, X. (2011) · Journal of Chemotherapy · doi:10.1179/joc.2011.23.5.295 · Cited by 42
Landsberg, J., Gaffal, E., Cron, M., Sirokay, J. D., Renn, M., & Tüting, T. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00744.x · Cited by 40
Wang, L., Liu, H., Chen, X., Zhang, M., Xie, K., & Ma, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045491 · Cited by 37
SHIP2 signaling in normal and pathological situations: Its impact on cell proliferation
Edimo, W. E., Schurmans, S., Roger, P. P., & Erneux, C. (2013) · Advances in Biological Regulation · doi:10.1016/j.jbior.2013.09.002 · Cited by 34
Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice
Chen, J., Zhang, X. D., & Proud, C. G. (2015) · Science Signaling · doi:10.1126/scisignal.aac8321 · Cited by 30
Self-citationHypoxia in the intestine or solid tumors: A beneficial or deleterious alarm signal?
Shehade, H., Oldenhove, G., & Moser, M. (2014) · European Journal of Immunology · doi:10.1002/eji.201444719 · Cited by 26
Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness
Bonecchi, R., Savino, B., Caronni, N., Celesti, G., Mantovani, A., & Locati, M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955337 · Cited by 14
Research works printed but not linked: 1
- Junjun, 2013, Detection of soluble B7-H4 molecules in serum of patients with breast cancer and its clinical significance, J Int Transl Med, 1, 215
Cited by
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akinleye, A., & Rasool, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0779-5 · Cited by 733
Mukherjee, A., Lordan, C., Ross, R. P., & Cotter, P. D. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1802866 · Cited by 690
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
Metadata
- Authors
- Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D.
- Affiliations
- The University of Queensland (AU)
- University of Newcastle Australia (AU)
- Corresponding author
- Zhang, X.D.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 27
- Issue
- 3
- Pages
- 409-416
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2253000935
- Cited by
- 767
- References
- 102
- Citations by year
- 2026: 31 · 2025: 49 · 2024: 73 · 2023: 82 · 2022: 77 · 2021: 112 · 2020: 105 · 2019: 72 · 2018: 72 · 2017: 61 · 2016: 31
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1344 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- NHMRC project (APP1083496)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, PD-1, immune evasion, cancer immunotherapy, PI3K signaling, MAPK signaling, hypoxia-inducible factor-1α, STAT3, transcriptional regulation, epigenetic regulation, microRNA, miR-34a, miR-200 family, cell proliferation, anti-PD-1
- MeSH terms
- B-Lymphocytes, Dendritic Cells, Humans, Neoplasms, Promoter Regions, Genetic, Protein Binding, T-Lymphocytes, Biomarkers, Tumor, Signal Transduction, NF-kappa B, Tumor Escape, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, MicroRNAs, Cell Proliferation, STAT3 Transcription Factor, Hypoxia-Inducible Factor 1, alpha Subunit, Natural Killer T-Cells, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.